Pemigatinib in previously treated Chinese patients with locally advanced or metastatic cholangiocarcinoma carrying <i>FGFR2</i> fusions or rearrangements: A phase <scp>II</scp> study - Concepedia

Concepedia

Publication | Open Access

Pemigatinib in previously treated Chinese patients with locally advanced or metastatic cholangiocarcinoma carrying <i>FGFR2</i> fusions or rearrangements: A phase <scp>II</scp> study

DOI Full Paper Access

20

Citations

26

References

2022

Year

Guo‐Ming Shi, Xiaoyong Huang, Tian‐Fu Wen, Tian‐Qiang Song, Ming Kuang, Haibo Mou, Lequn Bao, Haitao Zhao, Hong Zhao, Xielin Feng,

Cancer Medicine

Abstract

The encouraging antitumor activity and favorable safety profile support the use of pemigatinib as a treatment in previously treated Chinese patients with cholangiocarcinoma and FGFR2 rearrangements.

References

	Year	Citations

Page 1